Loyal's Life-Extending Drug for Large Dogs Receives Conditional FDA Approval

The experimental treatment, LOY-001, could add at least one year to the lifespan of larger dogs, with plans for market launch by 2026.

San Francisco biotech startup Loyal has received a conditional approval from the FDA for its experimental drug LOY-001, designed to extend the lifespan of larger dogs.
The drug works by reducing the levels of insulin-like growth factor, known as IGF-1, which is connected to body size in humans and dogs and is found at higher levels in larger breeds.
Loyal anticipates that LOY-001 could result in at least one year of healthy life span extension for dogs and plans to bring the drug to market by 2026.
The company is also developing two other products: a daily pill version of LOY-001 and another pill to improve metabolic fitness in older dogs.
Some experts have expressed concerns about the potential long-term effects of reducing IGF-1 levels in dogs, urging caution until more research is conducted.